机构：[1]Department of Urology, The Institution of Urology, 34753West China Hospital of Sichuan University, Chengdu, China.[2]Institute of Oncology Research (IOR), Bellinzona, Switzerland.[3]The Clinical Medical College of Lanzhou University, Lanzhou, China.[4]Department of General Medical, Medical Affairs Division, 34753West China Hospital of Sichuan University, Chengdu, China.
The aim was to evaluate the causes of death for patients with localized, regional and metastatic penile cancer (PeCa) after diagnosis.PeCa patients diagnosed during 2004-2018 in the Surveillance, Epidemiology, and End Results program database were identified. Causes of deaths including PeCa, second malignant tumors (SMTs) and non-tumor diseases were analyzed, as well as the standardized mortality ratio (SMR) of each cause.For localized PeCa, 800 of 2155 patients died during the follow-up. 24.9% of all deaths were due to PeCa. 18.0% and 57.1% deaths were due to SMTs and non-tumor causes. Main SMTs included cancers of lung and bronchus (n = 40) and skin (n = 11) with significantly increased SMRs of 1.71 (1.22-2.33) and 4.82 (2.41-8.63). Mortality risks of other SMTs were mostly similar with the general populations. Main causes of non-tumor diseases included diseases of heart [n = 172, SMR: 1.66 (1.42-1.93)], COPD and allied cond [n = 38, SMR: 1.63 (1.15-2.24)], and cerebrovascular diseases [n = 33, SMR: 1.71 (1.17-2.4)]. For regional PeCa, 679 of 1310 patients died including 43.5% PeCa, 14.8% SMTs and 26.6% non-tumor causes. The mortality risks of cancers from lung and bronchus [SMR: 2.41 (1.53-3.62)], skin [SMR: 6.41 (2.35-13.95)] and testis [SMR: 149.35 (18.09-539.5)] were significantly increased. Main non-tumor causes of death included diseases of heart [n = 71, SMR: 1.77 (1.38-2.23)], COPD and allied cond [n = 17, SMR: 1.85 (1.08-2.95)] and diabetes mellitus [n = 16, SMR: 3.62 (2.07-5.88)]. For distant diseases, 109 of 132 patients died including 76 (69.7%) died for PeCa itself, 24 (22.0%) died for SMTs and 9 (8.3%) died for non-tumor diseases. The majority of PeCa deaths (67.1%) and SMTs deaths (79.2%) occurred within 1 year after the diagnosis of PeCa.We firstly analyzed the SMTs and non-tumor causes of death and morality risks of each cause for PeCa patients, which provided valuable information for PeCa patients on disease prevention and health care during their survivorship.
基金：
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
This work was supported by a Key Project of National Natural
Science Foundation of China; Grant ID: 8177060452; Project of
Science and Technology Department of Sichuan Province, Grant
ID: 2021YFS0117; and Project of Science and Technology
Department of Chengdu City, Sichuan Province, Grant ID:
2021YF0500717SN.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Urology, The Institution of Urology, 34753West China Hospital of Sichuan University, Chengdu, China.[2]Institute of Oncology Research (IOR), Bellinzona, Switzerland.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, The Institution of Urology, 34753West China Hospital of Sichuan University, Chengdu, China.[*1]Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Wuhou District, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Song Pan,Wu Xiaotian,Yang Luchen,et al.Second Malignant Tumors and Non-Tumor Causes of Death for Patients With Penile Cancer During Their Survivorship[J].Cancer control : journal of the Moffitt Cancer Center.2022,29:10732748221134789.doi:10.1177/10732748221134789.
APA：
Song Pan,Wu Xiaotian,Yang Luchen,Ma Kai,Liu Zhenghuan...&Dong Qiang.(2022).Second Malignant Tumors and Non-Tumor Causes of Death for Patients With Penile Cancer During Their Survivorship.Cancer control : journal of the Moffitt Cancer Center,29,
MLA：
Song Pan,et al."Second Malignant Tumors and Non-Tumor Causes of Death for Patients With Penile Cancer During Their Survivorship".Cancer control : journal of the Moffitt Cancer Center 29.(2022):10732748221134789
